Initial intravenous γ-globulin treatment failure in Iranian children with Kawasaki disease

Kaohsiung Journal of Medical Sciences

Volumn 21, Issue 9, 2005, Pages 401-404

  Kashef, Sara ^a   Safari, Mojgan ^a   Amin, Reza ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coronary artery disease; Intravenous immunoglobulin; Kawasaki disease

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOGLOBULIN;

AGE; ARTICLE; CHILD; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; FEVER; GENDER; HUMAN; INFANT; IRAN; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE;

EID: 27144526484     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70141-x     Document Type: Article

References (19)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergy 1967;16:178-222.
2. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome prevailing in Japan. Pediatrics 1974;54:271-6.
3. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7.
4. Kato H, Koike S, Yamamoto M, et al. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr 1975;86:892-8.
5. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
6. Kato H, Ichinose E, Yoshika F, et al. Fate of coronary aneurysms in Kawasaki disease. Serial coronary angioplasty and long-term follow-up study. Am J Cardiol 1981;49:1758-66.
7. Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analysis in 195 cases. J Pediatr 1986;108:923-7.
8. Kato H, Inoue O, Akagi T. Kawasaki disease: cardiac problems and management. Pediatr Rev 1988;9:209-17.
9. Kato H, Sugimura T, Akagi T, et al. Long term consequences of Kawasaki disease: a 10-21 year follow-up study of 594 patients. Circulation 1996;94:1379-85.
10. Barron KS, Shulman ST, Rowley K, et al. Report of the National Institutes of Health Workshop on Kawasaki Disease. J Rheumatol 1999;26:1170-90.
11. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.
12. Sadeghi E, Amin R, Ajamee GH. Kawasaki syndrome: the Iranian experience. East Mediterr Health J 2001;7:16-25.
13. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gammaglobulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8.
14. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78.
15. Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10.
16. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8.
17. Dale RC, Saleem MA, Daw S, et al. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 2000;137:723-6.
18. Tse SM, Silverman ED, McCrindle BW, et al. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002;140:450-5.
19. Fong NC, Hui CK, Li CK, et al. Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol 2004;25:31-4.